Lysodren (mitotane)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Mitotane, an adrenocortical cytotoxic agent, is an antineoplastic agent and selective inhibitor of adrenocortical function.
USES: Mitotane is used to treat cancer of the adrenal glands. It works by slowing the growth of or killing adrenal gland cells and also decreases the amount of hormones made by the adrenal gland.
Generic name: mitotane
Pronunciation: (MYE-toe-tane)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Lysodren
Indications
The following indications are listed for Lysodren:
- Adrenal Cortex Carcinoma
Also known as: Adrenal Carcinoma, Adrenal Cortex Cancer, Adrenal Cortex Malignancy, Adrenal Cortical Adenocarcinoma, Adrenocortical Carcinoma, Cortex Glandulae Suprarenalis Cancer, Suprarenal Cortex Cancer.
Dosing
Dosage of mitotane must be based on the clinical response and tolerance of the patient in order to obtain optimum therapeutic results with minimum adverse effects. Since mitotane causes adrenocortical insufficiency in most patients, replacement steroid therapy is usually necessary. (See Cautions: Precautions and Contraindications.) In order to minimize or prevent the potential adverse effects of adrenocortical insufficiency, many clinicians recommend that replacement steroids be started (and continued) when treatment with mitotane is initiated, rather than after signs of adrenocortical insufficiency appear.
Mitotane is administered orally.
To minimize risk of dermal exposure, impervious gloves should be worn during handling of mitotane tablets or bottles of mitotane tablets in all settings, including storerooms, pharmacies, clinical settings, and home healthcare settings. Use of impervious gloves is recommended at all times during handling of mitotane tablets or bottles containing mitotane tablets, including unpacking and inspection, transport within a facility, and dose preparation and administration.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Animal reproduction studies have not been performed with mitotane. It is not known whether mitotane can cause fetal harm when administered to pregnant women or can affect reproduction capacity. Mitotane should be used during pregnancy only when clearly needed. The prolonged elimination of mitotane from the body after discontinuance of the drug should be considered.
It is not known whether mitotane is distributed into milk. Because of the potential for serious adverse reactions to mitotane in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman. The prolonged elimination of mitotane from the body after discontinuance of the drug should be considered.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.